Skip to main content

Table 3 Univariate analysis (OS) of the pooled dataset including real-world and clinical trial patients

From: Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from second-line immunotherapy in NSCLC

Variable

n

OR (95%CI)

P-value

Population

 Trial patients

292

Reference

 

 Real-world patients

141

1.13 (0.88-1.44)

0.34

Age (years)

  < 70

349

Reference

 

  ≥ 70

84

1.25 (0.94-1.66)

0.118

Gender

 Male

225

Reference

 

 Female

208

0.92 (0.73-1.15)

0.454

Stage

 IV

413

Reference

 

 IIIB

20

0.85 (0.48-1.22)

0.584

ECOG PS

 0

128

Reference

 

 1

298

1.95 (1.48-2.55)

< 0.001

 2

7

3.82 (1.75-8.33)

0.001

Presence of brain metastases

 No

374

Reference

 

 Yes

59

1.35 (0.99-1.85)

0.059

Histology tumor

 Adenocarcinoma

400

Reference

 

 Large cell carcinoma

15

1.24 (0.68-2.26)

0.488

 Adenosquamous

3

0.94 (0.23-3.79)

0.932

 Other

11

0.59 (0.24-1.43)

0.246

 Not otherwise specified (NOS)

3

2.45 (0.78-7.65)

0.123

PD-L1 expression

  < 1%

141

Reference

 

 1-49%

86

0.92 (0.66-1.28)

0.606

  > 50%

76

0.53 (0.36-0.77)

0.001

 Unknown

130

1.24 (0.94-1.63)

0.13

  1. ECOG PS Eastern Cooperative Oncology Group Performance Score, PD-L1 Programmed death-ligand 1, OR Odds Ratio